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ABSTRAK
Latar belakang: radiofrequency ablation (RFA) saat ini semakin luas dipergunakan sebagai terapi alternatif 
reseksi pada pasien dengan karsinoma sel hati (KHS). Bahkan pada ukuran nodul kurang dari 2 cm, RFA dapat 
menjadi lini utama pada kasus tersebut. Reseksi merupakan terapi utama dan salah satu terapi kuratif pada nodul 
dengan kriteria Milan, tetapi harus dipertimbangkan toleransi operasi pada pasien yang akan menjalani reseksi. 
Pada laporan kasus berdasar bukti ini kami bertujuan memperlihatkan efektivitas RFA dibandingkan reseksi 
dalam hal kesintasan, tetapi pada KHS nodul tunggal berukuran lebih dari 5 cm. Metode: pencarian artikel 
dilakukan dengan menggunakan mesin pencari PubMed, Scopus, Web of Science, dan CINAHL dari EBSCO 
dengan kata kunci “hepatocellular carcinoma”, “single nodule”, “radiofrequency ablation”, “resection”, 
dan “survival”. Artikel dibatasi pada artikel berbahasa Inggris dengan pertanyaan klinis “Pada pasien 
dengan KHS nodul tunggal berukuran lebih dari 5 cm, apakah RFA lebih baik dibandingkan dengan reseksi 
untuk memperpanjang kesintasan?” Hasil: didapatkan tiga artikel penelitian retrospektif dengan satu artikel 
menggabungkan terapi RFA dan injeksi etanol dalam analisis dan satu penelitian menggabungkan RFA dengan 
transarterial chemoembolization (TACE) dalam analisisnya. Dari ketiga penelitian tersebut memperlihatkan 
penurunan risiko absolut 33% sampai peningkatan risiko absolut 60,6%. Kesimpulan: seluruh penelitian 
menjadikan RFA sebagai alternatif reseksi bila reseksi tidak dapat dilakukan yang berarti tingkat keparahan 
lebih tinggi pada RFA, sehingga sulit mengambil kesimpulan bahwa RFA memberikan kesintasan lebih buruk.
Kata kunci: karsinoma sel hati, radiofrequency ablation, reseksi.
ABSTRACT
Background: nowadays, radiofrequency ablation (RFA) is applied widely as an alternative therapy of resection 
in patient with hepatocellular carcinoma (HCC). Moreover, in single nodule with size of less than 2 cm, RFA may 
be the primary treatment. Although resection is the main treatment and one of the curative treatments in nodule 
meeting Milan criteria, it needs consideration of risk stratification for surgical resection. This report was aimed 
to search evidence of RFA compared with RFA in term of survival in patient with HCC single nodule size of more 
than 5 cm. Methods: the searching was done using PubMed, Scopus, Web of Science, dan CINAHL from EBSCO 
with keyword of “hepatocellular carcinoma”, “single nodule”, “radiofrequency ablation”, “resection”, and 
“survival”. The limitation of the article was English with clinical question of “In patient with HCC single nodule 
size of more than 5 cm, was RFA more superior in resection in term of survival?”. Results: there were three articles 
with retrospective studies. One of the article combined RFA and percutaneous ethanol injection in the analysis, 
meanwhile another article combined RFA and transarterial chemoembolization. These articles showed conflicting 
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data that showed absolute risk reduction of 33% till absolute risk increment of 60.6%. Conclusion: all studies used 
RFA as the alternative of resection when the the tumor was unresectable which means the severity was higher in 
RFA group. Hence, we can not solely conclude that RFA resulted in worse survival.
Keywords: hepatocellular carcinoma, radiofrequency ablation, resection.
INTRODUCTION
Hepatocellular carcinoma is responsible for 
90% of liver cancer and is the second highest 
cause of cancer mortality in the world. Most of 
HCC are caused by hepatitis B and/or hepatitis 
C, mainly in patients with liver cirrhosis.1
Therapy for HCC includes resection, liver 
transplant, local ablation (includes radiofrequency 
ablation), transarterial chemoembolization 
(TACE), radiation, and systemic therapy. The 
decision of treatment depends on nodule size, 
nodule number, vascular invasion, metastasis, 
liver function (Child-Pugh score), and also 
performance status. National, regional, or 
international guideline has their own algorithms 
that have some differences. Meanwhile, in some 
condition, the treatment is needed to be decided 
by the multidisciplinary team.
According to Asia Pacific Association for 
the Study of the Liver (APASL)1 and Indonesian 
Liver Cancer Study Group (ILCSG),2 resection 
is the first-line curative treatment for HCC in 
patient of Child-Pugh A, but ILCSG along with 
European Association for the Study of the Liver 
(EASL)3 has less strict criteria that include normal 
bilirubin, platelet ≥100,000/ml and without portal 
hypertension (≤10 mmHg). It is recommended 
that the resection is done using Milan criteria, of 
which diameter less than 5 cm or maximal three 
nodules with size of less than 3 cm without any 
vascular invasion or metastasis.1,2 ILCSG stated 
resection may be done in single nodule with size 
of more than 5 cm and located in peripheral liver.2 
It is clear that nodule size of more than 5 cm which 
was resected had worse outcome.4
Ablation, particularly radiofrequency 
ablation (RFA) is recommended in HCC patient 
with Child-Pugh A or B and multiple nodule ≤3 
of size ≤3 cm. Moreover, it is the main treatment 
in nodule with size of ≤2 cm.1,2 ILCSG2 and 
EASL3 recommend RFA as alternative in patient 
with single nodule size of ≤5 cm. There is still no 
recommendation about the applicability of RFA 
in single nodule >5 cm.
There are also no clear recommendation 
about the treatment choice in patient with 
HCC single nodule size of >5 cm. Hence, this 
evidence-based case report was aimed to search 
the evidence whether RFA was better than 
resection in single nodule size of >5 cm.
CLINICAL QUESTION
A-62 year old man was diagnosed with 
HCC when he was screened for surveilance with 
ultrasound because of hepatitis B infection. The 
patient had a comorbid of coronary artery disease 
and underwent coronary bypass 5 years ago and 
still consumes clopidogrel and aspilet. The patient 
also had hypertension and it was controlled 
with amlodipin 10mg once daily. There was no 
complaint of sleep disturbance or other complaints 
of hepatic encephalopathy. No abnormality was 
found in physical examination. Ascites was not 
found at physical or radiological examination. 
AFP showed 4.7 IU/mL, HBsAg was positif, 
albumin 4.0 mg/dL, bilirubin total 0.47 mg/dL, 
and INR 1.02. The liver status was Child-Pugh 
A. Triple-phase abdominal computed tomography 
showed single nodule with size of 5.4x4.2x3.9 cm3 
in segment 4A of liver. There was no metastasis. 
The patient asked whether there was another 
option (like RFA) than resection considering the 
comorbidity of the patient.
Based on the information from the presented 
case, the formulation of clinical question and 
PICO framework are as follows:
• P : Hepatocellular carcinoma single nodule 
size of >5 cm.
• I : Radiofrequency ablation
• C : Resection
• O : Survival
In HCC patients with single nodule size of 
>5 cm, how was the survival between RFA and 
resection?
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METHODS
The articles were searched in PubMed, 
CINAHL (EBSCO), Web of Science, and 
Scopus on 11th Desember 2017, with keywords 
of hepatocellular carcinoma, single nodule, 
radiofrequency ablation, resection, and survival, 
but in PubMed we omited the survival because 
of the lack of results (Table 1). Search strategy 
and the description including the inclusion and 
exclusion criteria was described in Figure 1.
Table 2. Search strategy according clinical question conducted in December 11th 2017
Search engine Description No. of articles
Web of Science TOPIC: (single nodule) AND TOPIC: (hepatocellular carcinoma) AND TOPIC: (radiofrequency ablation) AND TOPIC: (resection) AND TOPIC: (survival) 66
Refined by: DOCUMENT TYPES: ( ARTICLE )
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, BKCI-S, BKCI-SSH, ESCI.
PubMed
((((("single person"[MeSH Terms] OR ("single"[All Fields] AND "person"[All 
Fields]) OR "single person"[All Fields] OR "single"[All Fields]) AND nodule[All 
Fields]) AND ("carcinoma, hepatocellular"[MeSH Terms] OR ("carcinoma"[All 
Fields] AND "hepatocellular"[All Fields]) OR "hepatocellular carcinoma"[All 
Fields] OR ("hepatocellular"[All Fields] AND "carcinoma"[All Fields]))) AND 




(single nodule) AND (hepatocellular carcinoma) AND (radiofrequency ablation) 
AND (resection) AND (survival) 27
Scopus
ALL ( "single nodule" )  AND  ALL ( "Hepatocellular carcinoma" )  AND  ALL ( 
"radiofrequency ablation" )  AND  resection  AND  ALL ( "survival" )  AND   
















Web of science PubMed EBSCO Scopus
66 15 7 104
Screening title and abstract
1 2 1 2
Article gathered : 6
Duplication : 3
Article used : 3
Figure 1. Flow chart of search strategy *without keyword of survival
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Selection
After searching the articles, we found six 
articles from four search engines. Three articles 
were duplicated, so there are three articles that 
were available and being appraised. All three 
articles are retrospective study.
RESULTS
Ogihara et al5 did the study retrospectively 
in two health centres in Honolulu, Japan. Total 
subjects were 87 HCC patients with single 
nodule recruited from period of 1995 until 2003. 
Of total 40 patients undergone RFA, 36 patients 
had unresectable lesions or low healthy liver 
volume and 4 patients refused to undergo surgery. 
They divided to two groups, lesion with ≤5 cm 
or >5 cm and resection or RFA so there are four 
groups. In this report, we only discuss the part 
of the study that the size of nodule >5cm, so 
there were 29 patients in resection group and 14 
patients in RFA group. This study also showed 
disease-free survival as an outcome. Patients 
who had recurency were treated depends on the 
lesion. Overall 1-year, 3-year, 5-year survival 
for therapy RFA vs resection were 65% vs 82%, 
65% vs 67%, 65% vs 37%, respectively. The 
median were >63 months in RFA vs 47 months 
in resection. Moreover, disease-free 1-year, 
3-year, 5-year survival were 53% vs 64%, 44% 
vs 40%, 0% vs 30% with median 20 months vs 
28 months in RFA vs resection, respectively. In 
RFA group, mean of age was older than resection 
group (72±10 years vs 60±13 years), but the 
tumor size was bigger in resection group than 
RFA group (10.2±4.7 cm vs 7.1±3.7 cm). Liver 
condition was worse in RFA group showed by 
more Child-Pugh B in RFA group than resection 
(43% vs 10%). The stage of HCC according to 
TNM classification was also more advance in 
RFA than resection (64% vs 7%).
Ruzzenente, et al6 also did a cohort study 
retrospectively from period of 1995—2009 in 
a hospital in Verona, Italy. The advantage of the 
study is they did a propensity case-matched study, 
so the baseline characteristics were similar. They 
included percutaneous local ablative therapies 
(LAT) and combined RFA and ethanol injection 
(PEI). In that period, there were total 181 patients 
undergone RFA and 297 patients undergone LAT 
(214 RFA and 83 PEI). The indication of LAT in 
this study were indicated when the location of 
the tumor was difficult or the patients refused to 
undergo liver resection, but all patients did not 
have absolute contraindication for resection. If 
the tumor relapsed, patients would be evaluated 
and undergone new treatment according to the 
indication. Unfortunately, in this study the tumor 
size was only maximum of 6 cm. After matching 
was done, there were 88 patients had resection 
and 88 had LAT. In LAT group, 88.6% of subjects 
were undergone RFA and 11.4% PEI. For single 
nodule with tumor size of ≥5 cm, there were 
only 13 cases undergone resection and 15 cases 
undergone LAT. The overall 1-year, 3-year, 5-year 
survival in LAT group versus resection group were 
78.3% vs 76.9%, 31.3% vs 68.4%, and 7.8% vs 
68.4%. Meanwhile for disease-free 1-year, 3-year, 
5-year survival in group LAT versus resection 
were 20% vs 83.3%, 6.7% vs 52.9%, 6.7% vs 
31.7%. Moreover, in case of single nodule with 
size of ≥5 cm, LAT gave hazard ratio of 3.8 (CI 
95%: 1.3—11.2) for overall survival and 5.6 (CI 
95%: 2—16) for disease-free survival.
Jung, et al7 also did a study retrospectively 
by taking the data in three hospitals in South 
Korea in 2004—2009 with total patients of 
HCC of 2131 patients. The treatment choice for 
resection was evaluated based on the location of 
the tumor, Child Pugh A or B, and indocyanine 
green retention rate at 15 minutes <25% which 
means there was no portal hypertension. Patients 
whose tumor was unresectable and who refused 
surgery would have RFA and transarterial 
chemoembolization (TACE). There were 124 
patients with single nodule with size of >5 cm 
and 41 patients (33.1%) undergone resection, 
15 patients (12.1%) undergone RFA ± TACE, 
and 68 patients (54.8%) undergone TACE 
alone. Child-Pugh B was in 5% resection cases, 
13% in RFA ± TACE, and 18% in TACE alone. 
Median of overall survival was 84.2 months for 
resection, 74.1 months for RFA ± TACE, and 
28.9 months for TACE alone. We measured the 
overall survival from the Kaplan Meier graphical 
analysis, because the authors did not write the 
data explicitely. The overall 1-year, 3-year, and 
5-year survival for RFA ± TACE vs resection 
were 91% vs 97.5%,  65% vs 85%, 65% vs 75%.
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Critical Appraisal
The appraisal forms obtained from toolkit in 
http://www.cebm.net/blog/2014/06/10/critical-
appraisal/ and presented in Table 2. All critical 
appraisals used therapy category in all articles 
although the studies were only retrospective.
DISCUSSION
From three articles that was found, none of 
the studies used randomized clinical trial, only 
retrospective studies, so the level of evidence 
is 2b. It is quite hard to compare resection and 
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curative treatment of HCC, although the usage 
of RFA is more widely used. RFA may have good 
prognostic as showed in Ho, et al’s study8 in San 
Fransisco, United States that showed in patients 
with HCC BCLC B, RFA had lower hazard ratio 
in 1-year survival than other locoregional therapy 
(TACE, transarterial embolization {TAE}, and 
PEI) (0.17 vs 0.38), but higher hazard ratio in 
5-year survival (0.63 vs 0.31).
In all studies found in this report, resection 
was the main treatment given to the patient 
if the tumor was resectable and the patients 
agreed, so the comparison between main 
treatment and alternative treatment was hard to 
be similar at the baseline. Only in the second 
study by Ruzzenente, et al6, the comparison 
may be thought similar because they were doing 
propensity matched study.
It was difficult to make head to head 
comparison as HCC patients might had a relapse 
and there would be other treatment applied to the 
patient. Hence it is difficult to make sure that the 
outcome was the result from the first treatment 
or the subsequent treatment.
The interesting result of this report is the 
wide range results of three studies. Ruzzenente, 
et al’s6 and Jung, et al’s7 studies showed resection 
was more superior, otherwise Ogihara, et al’s5 
study showed RFA was more superior. RFA was 
also superior in the meta analysis of Changyong, 
et al9 which included 4812 patients with HCC 
size of  ≤7 cm (2419 patients in RFA group and 
2393 patients in resection group), but there is 
no specific analysis among group with nodule 
>5 cm. They showed overall 3-year and 5-year 
survival was significantly better in RFA group, 
but we need to put note that from 25 studies 
included in the meta analysis, only two studies 
had tumor size of ≤7 cm and one study of ≤6 cm.
Ogihara, et al.5 showed there was decreasing 
of overall survival of resection in patient with 
single nodule >5 cm among 1-year, 3-year, 5-year 
survival from 82% to 67% to 37%, meanwhile in 
RFA groups, the overall survival was stagnan of 
65% among till 5 years. The most common cause 
of death of resection and RFA were secondary to 
liver failure in 35% of deaths and 100% of deaths 
among each group. Unfortunately the authors 
did not differentiate the cause of death between 
nodule >5 cm and ≤5 cm.
In two studies which showed resection was 
more superior, there were also some notes. 
Ruzzenente, et al6 combined two LAT, e.g.: 
RFA and PEI in the analysis, meanwhile Jung, 
et al7 combined RFA with/without TACE, so 
the efficacy of the treatment is not RFA alone. 
From Jung, et al’s study,7 it is clear that by 
adding RFA would increase survival than 
TACE alone. Combination RFA and TACE in 
HCC intermediate class (beyond Milan criteria, 
include single nodule >5 cm) was proved to 
increase survival in another study with difference 
in median reached 31.7 months than supportive 
therapy alone.10 Moreover, in a study by Pan, 
et al11 showed combination of RFA and TACE 
for tumor size ≤7 cm beyond Milan criteria was 
significantly increased median overall survival 
when compared with resection (52 months vs 
45 months). Meanwhile, in the earlier stage of 
HCC that is still included in Milan criteria, RFA 
showed more superior than TACE alone both 
in overall survival and also progression-free 
survival, particularly after one year.12 Among 
HCC BCLC B with single nodule with size of 
>5 cm, TACE alone was not better than resection 
in terms of overall 1-year, 3-year, and 5-year 
survival.13
The advantage of the study by Ruzzenente, 
et al6 is they did matching in the analysis, 
comparison to similar in baseline characteristics, 
but the largest tumor size in this studies only 
6 cm. Other study by Parisi, et al14 in Perugia, 
Italy compared RFA and resection in single 
nodule with size of >3 and ≤6 cm, but no specific 
analysis in size of >5cm. It showed that among 
Child-Pugh A, resection and RFA was not 
different in median survival (40 months vs 40 
months), but resection was significantly better 
than RFA among patients with Child-Pugh B 
(44 months vs 30 months). From those studies, 
we may infer that resection was still superior in 
tumor up to 6 cm than RFA, although it is not 
proven in Child-Pugh A group.
On the other hand, Ogihara, et al5 showed 
that the baseline charateristics were worse in 
RFA group in terms of age, Child-Pugh and TNM 
stage, but not in tumor size. With these baseline, 
they found RFA was better than resection in 
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single nodule size of >5cm. Moreover, only 
in this study, the RFA is not combined with 
other modalities. We also need to consider the 
technique of RFA and the type of the machine 
and puncture, because it will also affect the result. 
Only Ogihara, et al5 mentioned the technique of 
RFA that was done clearly.
In the point of view of quality of life, Chie, et 
al15 showed ablation was worse than surgery and 
embolization. The components of quality of life 
that were lower were dyspnea, loss of appetite, 
body image, and role of life. Meanwhile, in 
surgery, the component of quality of life that was 
impaired was only pain. They also performed 
the adjustment for patients’ characteristics and 
severity of cases and still found ablation had 
worse outcome quality of life, but there was no 
explanation the cause of this result.
CONCLUSION
We may conclude from this report that RFA 
can still be used in the single nodule with a size 
of >5 cm, although resection is still the first-line 
treatment when the patient has the proper criteria 
and reachable location. Resection may be still 
superior till size of 6 cm. RFA combined with 
TACE when the size is bigger may have more 
benefit than RFA alone.
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